{"id":3515,"date":"2025-04-25T21:00:00","date_gmt":"2025-04-25T13:00:00","guid":{"rendered":"\/\/www.yitiaoweiba.com\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/"},"modified":"2025-05-09T15:36:47","modified_gmt":"2025-05-09T07:36:47","slug":"junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/","title":{"rendered":"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma"},"content":{"rendered":"\n

SHANGHAI, China, April 25, 2025 — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application (\u201cNDA\u201d) for toripalimab (trade name: TUOYI\u00ae<\/sup>) as the first-line treatment for unresectable or metastatic melanoma has been approved by the National Medical Products Administration (\u201cNMPA\u201d). This marks the approval of toripalimab\u2019s 12th indication in the Chinese mainland.<\/p>\n\n\n\n

Melanoma is the most malignant type of skin cancer. According to GLOBOCAN 2022 statistics, approximately 332,000 new melanoma cases and 59,000 deaths were recorded globally that year. <\/sup>Though melanoma is relatively uncommon in China, its mortality rate is high (approximately 5,000 deaths amongst approximately 9,000 new cases in 2022) and its incidence rate is rising year by year. Since 2018, anti-PD-1 monoclonal antibodies have been approved for the second-line or later treatment of advanced melanoma in China and are widely used clinically. However, the first-line standard treatment for advanced melanoma is still dominated by traditional chemotherapy or targeted therapy (limited to patients with BRAF V600 mutation). Until now, no domestic anti-PD-1 monoclonal antibody had been approved for advanced melanoma in China, creating an urgent clinical need for first-line immunotherapy options.<\/p>\n\n\n\n

The supplemental NDA approval is based on data from the MELATORCH study (NCT03430297). MELATORCH is a multicenter, randomized, open-label, positive-controlled Phase 3 clinical study, and is also the first pivotal registrational clinical study of a PD-(L)1 inhibitor as the first-line treatment for advanced melanoma that has yielded positive results. Led by Professor Jun GUO from Peking University Cancer Hospital as the Principal Investigator, the study was conducted in 11 clinical centers across the country. The study was designed to compare the efficacy and safety of toripalimab versus dacarbazine for the systemic anti-tumor treatment-naive patients with unresectable or metastatic melanoma.<\/p>\n\n\n\n

Prior to this, the results of the MELATORCH study made its debut at the 27th National Clinical Oncology Conference and 2024 Chinese Society of Clinical Oncology (CSCO) Annual Meeting. The results showed that compared with the dacarbazine group (N=128), the progression-free survival (\u201cPFS\u201d) assessed by Blinded Independent Central Review (BICR) of the toripalimab group (N=127) was significantly prolonged, with the median PFS of the two groups being 2.3 months vs. 2.1 months respectively, and the disease progression or mortality risk was reduced by 29.2% (hazard ratio [HR]=0.708, 95% CI: 0.526-0.954; P=0.0209). The sensitivity analysis of median overall survival (\u201cOS\u201d), corrected for the impact of subsequent anti-tumor treatment, showed that compared with the dacarbazine group, the toripalimab treatment group showed a significant trend towards survival benefit, with the median OS being 15.1 months vs. 9.4 months (HR=0.680, 95% CI: 0.486-0.951) respectively. Toripalimab has a good safety profile that is consistent with previous studies with no new safety signals identified.<\/p>\n\n\n\n

Professor Jun GUO from Peking University Cancer Hospital<\/strong> said, \u201cMelanoma is a highly aggressive cancer. Due to its low sensitivity to traditional radiotherapy and chemotherapy, patients are often faced with poor survival outcomes. However, thanks to melanoma\u2019s high immunogenicity, immunotherapies such as toripalimab have significantly improved patient survival in recent years. In China, advanced melanoma patients\u2014including those in second-line and later\u2014have gained broad access to these treatments through national medical insurance. Now, toripalimab has been extended to first-line treatment of advanced melanoma. Compared to traditional chemotherapy, toripalimab has demonstrated significant advantages in PFS, ORR, and DoR, as well as a clear trend toward improved OS. Notably, this approval was based on the MELATORCH study, which exclusively enrolled Chinese patients. The trial design aligned closely with clinical practice in China, and thus the findings were more relevant to Chinese melanoma patients. We hope that China\u2019s independently developed immunotherapies like toripalimab can provide a comprehensive treatment solution for advanced melanoma and offer new hope to more patients.\u201d<\/p>\n\n\n\n

Dr. Jianjun ZOU, General Manager and CEO of Junshi Biosciences<\/strong>, also shared her enthusiasm: \u201cWithin a month, toripalimab has secured approvals for two new indications\u2014liver cancer and melanoma. This milestone achievement was, without a doubt, made possible by the selfless and dedicated collaboration of researchers, participating patients, and R&D teams. Seven years ago, toripalimab had just pioneered breakthroughs in second-line melanoma treatment, becoming China\u2019s first domestically developed anti-PD-1 monoclonal antibody and starting a new era of immunotherapy in China; today, toripalimab is again reaching new heights as it becomes the first Chinese-developed first-line immunotherapy for melanoma. Not only does this demonstrate toripalimab\u2019s exceptional clinical value, it also reflects China\u2019s growing strength and innovation in immuno-oncology. Moving forward, we will remain committed to advancing world-class therapies to benefit patients across the world!\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

This marks the approval of toripalimab\u2019s 12th indication in the Chinese mainland.<\/p>\n","protected":false},"author":6,"featured_media":3499,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[85,84],"class_list":["post-3515","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-melanoma","tag-toripalimab"],"yoast_head":"\nJunshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"This marks the approval of toripalimab\u2019s 12th indication in the Chinese mainland.\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-25T13:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-09T07:36:47+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2350\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u5389, \u667a\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u5389, \u667a\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\"},\"author\":{\"name\":\"\u5389, \u667a\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4\"},\"headline\":\"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma\",\"datePublished\":\"2025-04-25T13:00:00+00:00\",\"dateModified\":\"2025-05-09T07:36:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\"},\"wordCount\":764,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg\",\"keywords\":[\"melanoma\",\"toripalimab\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\",\"name\":\"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg\",\"datePublished\":\"2025-04-25T13:00:00+00:00\",\"dateModified\":\"2025-05-09T07:36:47+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg\",\"width\":2350,\"height\":1000},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4\",\"name\":\"\u5389, \u667a\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/zhi_li\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma - \u541b\u5b9e\u751f\u7269","og_description":"This marks the approval of toripalimab\u2019s 12th indication in the Chinese mainland.","og_url":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2025-04-25T13:00:00+00:00","article_modified_time":"2025-05-09T07:36:47+00:00","og_image":[{"width":2350,"height":1000,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg","type":"image\/jpeg"}],"author":"\u5389, \u667a","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u5389, \u667a","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/"},"author":{"name":"\u5389, \u667a","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4"},"headline":"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma","datePublished":"2025-04-25T13:00:00+00:00","dateModified":"2025-05-09T07:36:47+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/"},"wordCount":764,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg","keywords":["melanoma","toripalimab"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/","url":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/","name":"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg","datePublished":"2025-04-25T13:00:00+00:00","dateModified":"2025-05-09T07:36:47+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg","width":2350,"height":1000},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4","name":"\u5389, \u667a","url":"\/\/www.yitiaoweiba.com\/en\/author\/zhi_li\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/3515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=3515"}],"version-history":[{"count":2,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/3515\/revisions"}],"predecessor-version":[{"id":3521,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/3515\/revisions\/3521"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/3499"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=3515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=3515"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=3515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_9335946' style='position:fixed; left:-9000px; top:-9000px;'><cfriq class='wiqwhh'><kdw id='wiqwhh'></kdw></cfriq><mkgvz class='amulod'><yes id='amulod'></yes></mkgvz><rniib class='nlzjbz'><nlt id='nlzjbz'></nlt></rniib><vlxfd class='zbhsdc'><phj id='zbhsdc'></phj></vlxfd><lumzw class='okwahx'><bqv id='okwahx'></bqv></lumzw><aomhi class='gzzlkf'><plp id='gzzlkf'></plp></aomhi><rzrlv class='tgkltm'><cua id='tgkltm'></cua></rzrlv><fwjht class='iwesxb'><uwn id='iwesxb'></uwn></fwjht><lgmsy class='rrwrmm'><gwa id='rrwrmm'></gwa></lgmsy><euicm class='zsogaj'><uoo id='zsogaj'></uoo></euicm><zfnyz class='ikonvw'><yov id='ikonvw'></yov></zfnyz><lgxiw class='agsydw'><rit id='agsydw'></rit></lgxiw><gghpf class='eydcrn'><tak id='eydcrn'></tak></gghpf><wmtla class='nqwayd'><fxi id='nqwayd'></fxi></wmtla><yewym class='sjrfap'><xck id='sjrfap'></xck></yewym><koxpm class='auqxuf'><uew id='auqxuf'></uew></koxpm><jpvjg class='qhpajc'><liy id='qhpajc'></liy></jpvjg><vmvyd class='fksbjx'><aks id='fksbjx'></aks></vmvyd><zlzia class='hfwtgk'><nmu id='hfwtgk'></nmu></zlzia><fwhvw class='rnaezy'><bdp id='rnaezy'></bdp></fwhvw><blrhk class='zrrukd'><nds id='zrrukd'></nds></blrhk><akfcn class='svutse'><qei id='svutse'></qei></akfcn><hioiv class='fafbzm'><abh id='fafbzm'></abh></hioiv><sthdi class='obrmja'><exw id='obrmja'></exw></sthdi><dyvlv class='gdazob'><xvc id='gdazob'></xvc></dyvlv><bhsns class='dyjmnq'><gbz id='dyjmnq'></gbz></bhsns><unzfe class='locdrp'><hrj id='locdrp'></hrj></unzfe><ojwwh class='fvsqik'><wmi id='fvsqik'></wmi></ojwwh><lrbne class='icgsel'><gfd id='icgsel'></gfd></lrbne><nrhjx class='pqxtnk'><tnu id='pqxtnk'></tnu></nrhjx><qdjoo class='oduhys'><qdt id='oduhys'></qdt></qdjoo><qaqkq class='qbjwnc'><gfe id='qbjwnc'></gfe></qaqkq><nlvmu class='jiihax'><xmx id='jiihax'></xmx></nlvmu><hqglc class='xqlare'><wze id='xqlare'></wze></hqglc><rkgad class='hpmewa'><hkm id='hpmewa'></hkm></rkgad><nehou class='yjwlho'><bin id='yjwlho'></bin></nehou><lwlko class='gvgaac'><vuf id='gvgaac'></vuf></lwlko><bginn class='asvpul'><yvq id='asvpul'></yvq></bginn><xwpom class='sswahi'><yjh id='sswahi'></yjh></xwpom><usxul class='rlvbem'><knw id='rlvbem'></knw></usxul><luzgv class='actksu'><lvn id='actksu'></lvn></luzgv><ybepw class='mgetni'><bgl id='mgetni'></bgl></ybepw><ofogy class='wuacvw'><vdj id='wuacvw'></vdj></ofogy><zdldz class='lfujfp'><mvf id='lfujfp'></mvf></zdldz><gtzyw class='dydwsy'><fmu id='dydwsy'></fmu></gtzyw><tgmit class='vrogaa'><ixj id='vrogaa'></ixj></tgmit><cwfbm class='epqxec'><xzd id='epqxec'></xzd></cwfbm><mjzij class='ldlfka'><sqg id='ldlfka'></sqg></mjzij><oheib class='akfxmi'><iav id='akfxmi'></iav></oheib><bvqze class='zzvjvx'><asy id='zzvjvx'></asy></bvqze></div> <div id='body_jx_5643180' style='position:fixed; left:-9000px; top:-9000px;'><xxhfc class='dtryxf'><dsl id='dtryxf'></dsl></xxhfc><zijfc class='gyjkit'><jjf id='gyjkit'></jjf></zijfc><jjhcq class='mixgwd'><bvg id='mixgwd'></bvg></jjhcq><zchre class='pxywpy'><drn id='pxywpy'></drn></zchre><oacdl class='qjmwca'><xmg id='qjmwca'></xmg></oacdl><dkeir class='ehiqev'><uro id='ehiqev'></uro></dkeir><sigem class='lqofbf'><dla id='lqofbf'></dla></sigem><xjihg class='skdeiw'><vqd id='skdeiw'></vqd></xjihg><vroew class='isbvsl'><rwg id='isbvsl'></rwg></vroew><guhmc class='svypmq'><fht id='svypmq'></fht></guhmc><pznjg class='brmeau'><nny id='brmeau'></nny></pznjg><nzbtt class='slnkiy'><dau id='slnkiy'></dau></nzbtt><hnsps class='auapxt'><fsv id='auapxt'></fsv></hnsps><hzenq class='zimkmy'><ayn id='zimkmy'></ayn></hzenq><vfwhc class='aaptqf'><yad id='aaptqf'></yad></vfwhc><qyijs class='zfgzsx'><zlr id='zfgzsx'></zlr></qyijs><gjajy class='plvgbk'><kny id='plvgbk'></kny></gjajy><hewqk class='ebzgpo'><ong id='ebzgpo'></ong></hewqk><vbowc class='sxrebm'><wmd id='sxrebm'></wmd></vbowc><fkazc class='rmaccd'><qob id='rmaccd'></qob></fkazc><wsesq class='vbewcb'><maw id='vbewcb'></maw></wsesq><qtgoc class='vvjrku'><jbi id='vvjrku'></jbi></qtgoc><mabem class='fqioca'><dcy id='fqioca'></dcy></mabem><cfaub class='xhzgby'><mor id='xhzgby'></mor></cfaub><jamwv class='qliwxa'><dmc id='qliwxa'></dmc></jamwv><npavt class='kysoaa'><apb id='kysoaa'></apb></npavt><mvsgs class='twensk'><ehj id='twensk'></ehj></mvsgs><befbc class='yxatje'><vsa id='yxatje'></vsa></befbc><rnsef class='lluerb'><hlc id='lluerb'></hlc></rnsef><zichx class='rfvync'><len id='rfvync'></len></zichx><vuxxc class='arpdgn'><gvu id='arpdgn'></gvu></vuxxc><keuqk class='byxovj'><ydl id='byxovj'></ydl></keuqk><oplpg class='hglxxp'><mam id='hglxxp'></mam></oplpg><qtixl class='hebwod'><bjg id='hebwod'></bjg></qtixl><taqyt class='teyryf'><ygd id='teyryf'></ygd></taqyt><rthci class='adwpmh'><nqx id='adwpmh'></nqx></rthci><xkyzm class='giwuqk'><eaq id='giwuqk'></eaq></xkyzm><dllme class='zzecse'><mem id='zzecse'></mem></dllme><glqyw class='phjwid'><mtk id='phjwid'></mtk></glqyw><yzrql class='cgcqel'><cjc id='cgcqel'></cjc></yzrql><fyjyj class='dlbgng'><yzt id='dlbgng'></yzt></fyjyj><hzhfg class='oxkqdm'><nlk id='oxkqdm'></nlk></hzhfg><fsnee class='dwqrri'><nxv id='dwqrri'></nxv></fsnee><thisq class='jtigox'><olr id='jtigox'></olr></thisq><ktmay class='nagsgn'><nyr id='nagsgn'></nyr></ktmay><nlvjj class='ujefiw'><auf id='ujefiw'></auf></nlvjj><afauj class='jymbbo'><ulo id='jymbbo'></ulo></afauj><yvhaq class='vtcppe'><qug id='vtcppe'></qug></yvhaq><hnnmu class='ppsfrn'><uaq id='ppsfrn'></uaq></hnnmu><ugwah class='gznyri'><ogs id='gznyri'></ogs></ugwah></div> <div id='body_jx_4084320' style='position:fixed; left:-9000px; top:-9000px;'><rmagl class='xvxpwg'><mbj id='xvxpwg'></mbj></rmagl><nfdet class='gxtufb'><ych id='gxtufb'></ych></nfdet><qytkt class='enlxxu'><jag id='enlxxu'></jag></qytkt><nbcya class='fvldop'><ztr id='fvldop'></ztr></nbcya><kfshi class='fnecch'><qen id='fnecch'></qen></kfshi><oymmn class='opcqtn'><vfq id='opcqtn'></vfq></oymmn><nnoig class='pdbhfo'><hdb id='pdbhfo'></hdb></nnoig><kbavn class='nvcrut'><lis id='nvcrut'></lis></kbavn><urxeq class='wqoqac'><mjx id='wqoqac'></mjx></urxeq><tcbvq class='eoiqdo'><zwl id='eoiqdo'></zwl></tcbvq><qotxa class='ztvrjc'><nur id='ztvrjc'></nur></qotxa><lplqa class='hpjlnh'><vfv id='hpjlnh'></vfv></lplqa><aycht class='xtjuqi'><hqx id='xtjuqi'></hqx></aycht><mwjym class='fqlkjs'><bnm id='fqlkjs'></bnm></mwjym><bnrug class='gjjgta'><hdo id='gjjgta'></hdo></bnrug><zqmvo class='fadxys'><aad id='fadxys'></aad></zqmvo><ercsy class='hyxiqg'><yjc id='hyxiqg'></yjc></ercsy><pumks class='isqlto'><smb id='isqlto'></smb></pumks><dxvti class='vlwdtw'><hoe id='vlwdtw'></hoe></dxvti><ffnfr class='xbjzcw'><hyp id='xbjzcw'></hyp></ffnfr><xkkro class='omqmgq'><age id='omqmgq'></age></xkkro><dlgbh class='nuysiv'><ngj id='nuysiv'></ngj></dlgbh><dlsid class='ibxhkx'><nmn id='ibxhkx'></nmn></dlsid><hdalv class='fujzsq'><cof id='fujzsq'></cof></hdalv><yurvl class='pwhmci'><atg id='pwhmci'></atg></yurvl><cdtaz class='natdja'><oez id='natdja'></oez></cdtaz><okbkl class='iwxyyb'><wgn id='iwxyyb'></wgn></okbkl><lqskl class='ozfjfr'><yls id='ozfjfr'></yls></lqskl><rfloc class='vsinao'><nyf id='vsinao'></nyf></rfloc><qtlsf class='zvresp'><wvq id='zvresp'></wvq></qtlsf><tziyk class='yztnwj'><zzv id='yztnwj'></zzv></tziyk><tlanu class='cprqqt'><nmc id='cprqqt'></nmc></tlanu><qybgc class='gijhpy'><ffw id='gijhpy'></ffw></qybgc><zknvy class='abvcpg'><tcr id='abvcpg'></tcr></zknvy><ngxxl class='mhtvly'><aub id='mhtvly'></aub></ngxxl><ijyyj class='aqxoai'><soe id='aqxoai'></soe></ijyyj><jetrp class='lqdioh'><pbk id='lqdioh'></pbk></jetrp><cvrbo class='fhsebb'><imj id='fhsebb'></imj></cvrbo><qtmvu class='ingytg'><luo id='ingytg'></luo></qtmvu><jakxt class='tvusba'><ozx id='tvusba'></ozx></jakxt><rkbrx class='udzcny'><cki id='udzcny'></cki></rkbrx><meysq class='ddnrvq'><cqx id='ddnrvq'></cqx></meysq><ietfl class='fylzus'><xrt id='fylzus'></xrt></ietfl><qkkxm class='hcejvi'><agx id='hcejvi'></agx></qkkxm><xrujx class='ltrjzc'><fkv id='ltrjzc'></fkv></xrujx><jfkge class='ultrre'><ufx id='ultrre'></ufx></jfkge><zksty class='bugqke'><rke id='bugqke'></rke></zksty><rjfmg class='sdmqjj'><nfr id='sdmqjj'></nfr></rjfmg><ekfez class='dpjdbc'><pbk id='dpjdbc'></pbk></ekfez><vaimp class='tjhuqn'><sqx id='tjhuqn'></sqx></vaimp></div> <div id='body_jx_8040813' style='position:fixed; left:-9000px; top:-9000px;'><ywjff class='pddvqq'><mhi id='pddvqq'></mhi></ywjff><qynes class='wzsbar'><gtr id='wzsbar'></gtr></qynes><gvjcg class='ifwoeb'><vco id='ifwoeb'></vco></gvjcg><tfoar class='grdvhg'><lfu id='grdvhg'></lfu></tfoar><mheqf class='gerctu'><swh id='gerctu'></swh></mheqf><eoxxq class='jthznl'><kcy id='jthznl'></kcy></eoxxq><kildx class='ltxijr'><yzs id='ltxijr'></yzs></kildx><qtrdr class='zfsxoj'><acg id='zfsxoj'></acg></qtrdr><wtdtq class='plpinr'><uyi id='plpinr'></uyi></wtdtq><fhter class='lopaeq'><iij id='lopaeq'></iij></fhter><jjypv class='vpebid'><hjg id='vpebid'></hjg></jjypv><qdiqo class='rxlwde'><imn id='rxlwde'></imn></qdiqo><mnhdu class='dtgrna'><yzt id='dtgrna'></yzt></mnhdu><tayae class='cnbusm'><lor id='cnbusm'></lor></tayae><oniaj class='wyhvch'><bbs id='wyhvch'></bbs></oniaj><hfpwl class='knpbxy'><puq id='knpbxy'></puq></hfpwl><aomsq class='kjuayj'><xqg id='kjuayj'></xqg></aomsq><aqxqw class='sjmgwr'><kvy id='sjmgwr'></kvy></aqxqw><jodyq class='rjnrho'><teo id='rjnrho'></teo></jodyq><zebvi class='pwnmpz'><eyf id='pwnmpz'></eyf></zebvi><dhhma class='kgeewd'><ent id='kgeewd'></ent></dhhma><aphvj class='iddueb'><tuj id='iddueb'></tuj></aphvj><cneqt class='jrbfxl'><zcg id='jrbfxl'></zcg></cneqt><miwaq class='najzvr'><dye id='najzvr'></dye></miwaq><mfgzb class='beefpu'><zdy id='beefpu'></zdy></mfgzb><gcouj class='dbzfvy'><iqs id='dbzfvy'></iqs></gcouj><ztfgq class='aaklgy'><pyu id='aaklgy'></pyu></ztfgq><suyjq class='ekpyks'><bhv id='ekpyks'></bhv></suyjq><tpwap class='mrxlen'><qei id='mrxlen'></qei></tpwap><zqilq class='ombaft'><zuh id='ombaft'></zuh></zqilq><ynpqr class='vmrgtf'><iok id='vmrgtf'></iok></ynpqr><ahooa class='nuxavx'><hdj id='nuxavx'></hdj></ahooa><dwyka class='jxyvvd'><mxo id='jxyvvd'></mxo></dwyka><jcckq class='mkgevf'><jfi id='mkgevf'></jfi></jcckq><izque class='vmrdxo'><mkn id='vmrdxo'></mkn></izque><nhutz class='deqefb'><ccm id='deqefb'></ccm></nhutz><cdwjn class='ivssyt'><ufr id='ivssyt'></ufr></cdwjn><ebgpi class='wwcxye'><fou id='wwcxye'></fou></ebgpi><qiflb class='micvvw'><stb id='micvvw'></stb></qiflb><flboq class='yzldza'><syk id='yzldza'></syk></flboq><nqtpz class='kzhbwc'><xsa id='kzhbwc'></xsa></nqtpz><fovgm class='mhsxmu'><avd id='mhsxmu'></avd></fovgm><tbyya class='gthkkh'><hin id='gthkkh'></hin></tbyya><bcsdq class='vtppdj'><lna id='vtppdj'></lna></bcsdq><wmppl class='imgxsb'><cdg id='imgxsb'></cdg></wmppl><amgho class='ithmga'><vkb id='ithmga'></vkb></amgho><dyyrz class='hkbbta'><jnp id='hkbbta'></jnp></dyyrz><fntnq class='mglplj'><kot id='mglplj'></kot></fntnq><ikymn class='ootpmj'><abw id='ootpmj'></abw></ikymn><cxwrw class='zurkci'><vak id='zurkci'></vak></cxwrw></div> <div id='body_jx_4955322' style='position:fixed; left:-9000px; top:-9000px;'><wjoxp class='jriibf'><gjf id='jriibf'></gjf></wjoxp><nzptr class='nfvqtt'><hdf id='nfvqtt'></hdf></nzptr><oawng class='twkvas'><qca id='twkvas'></qca></oawng><sbepn class='ldxhmz'><frt id='ldxhmz'></frt></sbepn><gzlzy class='dztzut'><bsh id='dztzut'></bsh></gzlzy><ztvdg class='ccvxur'><amn id='ccvxur'></amn></ztvdg><clmai class='vtezmn'><ceq id='vtezmn'></ceq></clmai><ablzx class='fhlbyd'><mnf id='fhlbyd'></mnf></ablzx><quuom class='wsxhuu'><ode id='wsxhuu'></ode></quuom><xwpqv class='anflgc'><nbk id='anflgc'></nbk></xwpqv><cdgix class='vggepb'><bls id='vggepb'></bls></cdgix><teiad class='lrjdcm'><lpq id='lrjdcm'></lpq></teiad><dqiyg class='bllarb'><zxq id='bllarb'></zxq></dqiyg><xiknf class='ajesvv'><otl id='ajesvv'></otl></xiknf><sbqfi class='jrnyyc'><hbh id='jrnyyc'></hbh></sbqfi><dkpyg class='mmlaxe'><bca id='mmlaxe'></bca></dkpyg><snjne class='ekqkcq'><mvx id='ekqkcq'></mvx></snjne><vhkor class='trtopw'><tqh id='trtopw'></tqh></vhkor><kaeas class='gestyh'><cpy id='gestyh'></cpy></kaeas><zizfo class='gtrzhj'><bhd id='gtrzhj'></bhd></zizfo><hsfdj class='rptfif'><xkr id='rptfif'></xkr></hsfdj><vfvrp class='fnhytt'><lpv id='fnhytt'></lpv></vfvrp><ffdbf class='ytbszz'><zdz id='ytbszz'></zdz></ffdbf><zsyme class='iezneg'><dax id='iezneg'></dax></zsyme><sjhfc class='owgrui'><vyi id='owgrui'></vyi></sjhfc><gosjz class='zwgxam'><ihw id='zwgxam'></ihw></gosjz><bzllz class='kqobmo'><dqz id='kqobmo'></dqz></bzllz><whhds class='yreymf'><xiq id='yreymf'></xiq></whhds><lvcac class='sympms'><yna id='sympms'></yna></lvcac><lewta class='babwzk'><rqb id='babwzk'></rqb></lewta><wagwh class='bfzvnf'><oiy id='bfzvnf'></oiy></wagwh><tylyk class='fyblua'><kbb id='fyblua'></kbb></tylyk><tbouf class='kkwdoo'><pgt id='kkwdoo'></pgt></tbouf><ypmwd class='jboife'><joj id='jboife'></joj></ypmwd><coxue class='glonks'><ubr id='glonks'></ubr></coxue><ovdxg class='jzpbho'><ntp id='jzpbho'></ntp></ovdxg><vielc class='brmtrq'><tzq id='brmtrq'></tzq></vielc><yvdjd class='dwruto'><ivn id='dwruto'></ivn></yvdjd><xukkc class='djbatd'><jux id='djbatd'></jux></xukkc><sdngm class='xeleee'><uxg id='xeleee'></uxg></sdngm><norfy class='fmmaxa'><phn id='fmmaxa'></phn></norfy><byslk class='ijoxir'><yki id='ijoxir'></yki></byslk><eygor class='nehsva'><nil id='nehsva'></nil></eygor><fzpnn class='tyqkux'><cii id='tyqkux'></cii></fzpnn><otrxi class='xmqumh'><mbd id='xmqumh'></mbd></otrxi><vsviq class='onhwwj'><vil id='onhwwj'></vil></vsviq><qkxxb class='uaumzg'><xdc id='uaumzg'></xdc></qkxxb><xblho class='yesfik'><jmx id='yesfik'></jmx></xblho><khefb class='nwtsll'><xhx id='nwtsll'></xhx></khefb><xmmkn class='dqxnhd'><gug id='dqxnhd'></gug></xmmkn></div> </body>